Novo Nordisk A/S stock dips after 2025 guidance cut. However, click for why NVO's strong GLP-1 prospects, growing pipeline, ...

On Tuesday, Novo took an axe to its financial outlook in a surprise corporate update call where it replaced its CEO with an ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

If you’ve spent any time in the real world lately, chances are you’ve heard of Ozempic, Wegovy, Mounjaro or semaglutide.

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

A growing number of people are turning to medications like Ozempic, Wegovy, and Mounjaro to aid in weight loss and manage ...